Repare Therapeutics Inc. (RPTX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Repare Therapeutics Inc. (RPTX) trades at $2.65 with AI Score 51/100 (Grade B). Repare Therapeutics Inc. is a clinical-stage precision oncology company focused on discovering and developing cancer therapies using its synthetic lethality approach. Market cap: $114.24M, Sector: Healthcare.
Price live · AI analysis from May 9, 2026Analyst Coverage for RPTX: RPTX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates RPTX against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
RPTX: 3/7 perspectives are bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Repare Therapeutics Inc. (RPTX) Healthcare & Pipeline Overview
Repare Therapeutics Inc. is a clinical-stage precision oncology company leveraging its SNIPRx platform to discover and develop targeted cancer therapies. The company's focus on synthetic lethality and DNA damage repair positions it within the competitive biotechnology landscape, with RP-3500 as its lead product candidate.
What Is the Investment Thesis for RPTX?
Repare Therapeutics Inc. presents a notable research candidate within the precision oncology space. The company's SNIPRx platform offers a systematic approach to discovering and developing targeted cancer therapies, potentially leading to a pipeline of novel drug candidates. A key value driver is the advancement of RP-3500 through clinical trials, with positive data readouts serving as significant catalysts. The company's focus on synthetic lethality and DNA damage repair addresses a critical area in cancer treatment. However, the company's negative profit margin of -608.3% highlights the financial risks associated with clinical-stage biotechnology companies. Successful commercialization of RP-3500 or other pipeline assets is crucial for long-term value creation.
Based on FMP financials and quantitative analysis
RPTX Key Highlights
- Repare Therapeutics operates in the precision oncology space, focusing on synthetic lethality.
- Lead product candidate RP-3500 targets solid tumors with specific DNA damage repair-related genomic alterations.
- SNIPRx platform enables systematic discovery of targeted cancer therapies.
- RP-6306 is in Phase I clinical trials for tumors with genetic alterations characterized by CCNE1 amplification.
- Gross Margin of 23.0% indicates potential for profitability upon successful commercialization.
Who Are RPTX's Competitors?
RPTX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ANAB AnaptysBio, Inc. | $67.29 | +8.00% | $2.90B | 79 |
| SNDX Syndax Pharmaceuticals, Inc. | $23.12 | +4.69% | $2.05B | 79 |
| ABCL AbCellera Biologics Inc. | $7.69 | -2.29% | $2.35B | 76 |
| CGEN Compugen Ltd. | $2.38 | +1.06% | $225.51M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $24.32 | +4.58% | $1.58B | 68 |
| IVBXF Innovent Biologics, Inc. | $10.15 | -13.05% | $17.61B | 68 |
| BCYC Bicycle Therapeutics plc | $4.50 | +3.56% | $312.62M | 68 |
| TLX Telix Pharmaceuticals Limited | $11.74 | -3.37% | $3.98B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RPTX's Key Strengths?
- Proprietary SNIPRx platform for drug discovery.
- Focus on synthetic lethality and DNA damage repair.
- Clinical-stage pipeline with RP-3500 as lead candidate.
- Experienced management team with expertise in oncology drug development.
What Are RPTX's Weaknesses?
- High cash burn rate due to ongoing research and development expenses.
- Dependence on successful clinical trial outcomes.
- Limited commercial infrastructure.
- Negative profit margin.
What Could Drive RPTX Stock Higher?
- RP-3500 clinical trial data readouts in the next 12-24 months.
- RP-6306 Phase I trial data expected in the next 18-36 months.
- Advancement of Polymerase Theta program through preclinical and early-stage clinical development.
- Potential strategic partnerships and collaborations with larger pharmaceutical companies.
What Are the Key Risks for RPTX?
- Financial-distress signal — its Altman Z-Score of -0.08 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-57.6%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Unfavorable clinical trial results for RP-3500 or other pipeline assets.
- Regulatory delays or rejection of drug approval applications.
- Competition from other biotechnology and pharmaceutical companies developing similar therapies.
- High cash burn rate and need for additional financing.
- Patent expirations and generic competition.
What Are the Growth Opportunities for RPTX?
- Expansion of RP-3500 into New Cancer Types: Repare has the opportunity to expand the application of RP-3500 to additional cancer types beyond its initial targets. This could involve conducting clinical trials in new patient populations or exploring combination therapies with other anti-cancer agents. The market for targeted cancer therapies is projected to reach $150 billion by 2028, providing a substantial opportunity for Repare to capture a larger share with successful clinical outcomes and regulatory approvals. Timeline: Ongoing clinical trials with potential data readouts in the next 12-24 months.
- Advancement of RP-6306 Through Clinical Trials: The successful advancement of RP-6306 through Phase I clinical trials represents a significant growth opportunity for Repare. Positive data from these trials could lead to further development and potential commercialization of RP-6306 for tumors with genetic alterations characterized by CCNE1 amplification. The market for CCNE1-targeted therapies is estimated at $5 billion annually, offering a substantial revenue opportunity for Repare. Timeline: Phase I trial data expected in the next 18-36 months.
- Development of the Polymerase Theta Program: Repare's Polymerase Theta program, targeting a synthetic lethality target associated with BRCA mutations and other genomic alterations, holds significant promise. Successful development of this program could lead to a novel therapy for patients with BRCA-mutated cancers, addressing a significant unmet medical need. The market for BRCA-targeted therapies is estimated at $8 billion, providing a substantial growth opportunity. Timeline: Preclinical and early-stage clinical development over the next 3-5 years.
- Strategic Partnerships and Collaborations: Repare can pursue strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its pipeline assets. These partnerships could provide access to additional funding, expertise, and resources, enhancing Repare's ability to bring its therapies to market. The value of such partnerships can range from $100 million to $1 billion or more, depending on the stage of development and the potential market opportunity. Timeline: Ongoing discussions with potential partners, with potential deals in the next 12-24 months.
- Expansion into New Geographic Markets: Repare has the opportunity to expand its operations into new geographic markets beyond Canada and the United States. This could involve conducting clinical trials in Europe or Asia, or establishing commercial operations in these regions. The global market for cancer therapies is expanding rapidly, particularly in emerging markets, providing a significant growth opportunity for Repare. Timeline: Potential expansion into Europe and Asia over the next 3-5 years.
What Opportunities Does RPTX Have?
- Expansion of RP-3500 into new cancer types.
- Advancement of RP-6306 and Polymerase Theta program through clinical trials.
- Strategic partnerships and collaborations with larger pharmaceutical companies.
- Expansion into new geographic markets.
What Threats Does RPTX Face?
- Competition from other biotechnology and pharmaceutical companies.
- Regulatory hurdles and delays in drug approval.
- Unfavorable clinical trial results.
- Patent expirations and generic competition.
What Are RPTX's Competitive Advantages?
- SNIPRx Platform: Proprietary, genome-wide, and CRISPR-enabled platform for discovering targeted cancer therapies.
- Synthetic Lethality Approach: Focus on exploiting vulnerabilities in cancer cells to selectively target and eliminate them.
- Expertise in DNA Damage Repair: Deep understanding of DNA damage repair pathways and their role in cancer development.
- Clinical-Stage Pipeline: Advanced pipeline of drug candidates in clinical development, including RP-3500 and RP-6306.
What Does RPTX Do?
Repare Therapeutics Inc., founded in 2016 and headquartered in Montreal, Canada, is a clinical-stage precision oncology company dedicated to discovering and developing novel cancer therapeutics. The company operates on the principle of synthetic lethality, a strategy that exploits vulnerabilities in cancer cells to selectively target and eliminate them while sparing healthy cells. Repare's core technology is its SNIPRx platform, a proprietary, genome-wide, and CRISPR-enabled system designed to systematically identify and develop highly targeted cancer therapies. This platform focuses on genomic instability, particularly in DNA damage repair pathways, which are often dysregulated in cancer cells. Repare's lead product candidate is RP-3500, an oral small molecule inhibitor targeting solid tumors with specific DNA damage repair-related genomic alterations. RP-3500 is currently under development for various cancer types exhibiting these alterations. In addition to RP-3500, Repare is also developing RP-6306, which is in Phase I clinical trials for tumors with genetic alterations characterized by CCNE1 amplification. The company's pipeline also includes the Polymerase Theta program, a synthetic lethality target associated with BRCA mutations and other genomic alterations. Repare Therapeutics operates primarily in Canada and the United States, focusing on advancing its pipeline through clinical trials and strategic partnerships.
What Products and Services Does RPTX Offer?
- Discovers and develops cancer therapeutics using a synthetic lethality approach.
- Utilizes the SNIPRx platform to identify and develop targeted cancer therapies.
- Focuses on genomic instability, including DNA damage repair, in cancer cells.
- Develops oral small molecule inhibitors for the treatment of solid tumors.
- Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Targets tumors with specific DNA damage repair-related genomic alterations.
- Develops therapies for tumors with genetic alterations characterized by CCNE1 amplification.
- Works on Polymerase Theta program, a synthetic lethality target associated with BRCA mutations.
How Does RPTX Make Money?
- Discovers and develops novel cancer therapeutics.
- Out-licenses or co-develops its drug candidates with pharmaceutical partners.
- Generates revenue through milestone payments and royalties from partnered programs.
- Retains commercial rights to certain drug candidates for independent development and commercialization.
What Industry Does RPTX Operate In?
Repare Therapeutics operates within the rapidly evolving biotechnology industry, specifically in the precision oncology segment. This sector is characterized by intense competition, high research and development costs, and stringent regulatory requirements. The market for targeted cancer therapies is expanding, driven by advancements in genomics and personalized medicine. Repare's focus on synthetic lethality and DNA damage repair positions it within a niche area of precision oncology, potentially offering a competitive advantage. The company competes with larger pharmaceutical companies and specialized biotechnology firms developing similar targeted therapies.
Who Are RPTX's Key Customers?
- Patients with solid tumors and specific DNA damage repair-related genomic alterations.
- Patients with tumors characterized by CCNE1 amplification.
- Pharmaceutical companies seeking to in-license or co-develop novel cancer therapeutics.
- Healthcare providers who prescribe and administer cancer therapies.
Net sellingInsider Activity
Over the past six months, Repare Therapeutics Inc. insiders filed 12 SEC Form 4 transactions — 12 sales and 0 purchases. On net that is roughly 1.7M shares disposed (about $2.8M), a signal worth weighing alongside the fundamentals.
FY2026 estForward Outlook
Wall Street analysts project Repare Therapeutics Inc. revenue of about $6.7M for fiscal 2026, with EPS near $-1.26.
F-Score 3/9Financial Health
Repare Therapeutics Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -0.08 places it in the distress zone, a signal of elevated financial risk.
ROE -58%Key Financial Metrics
Return on equity for Repare Therapeutics Inc. stands at -57.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -57.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -61.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 10.71 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -63.4%, the inverse of the P/E and a quick read on earnings relative to price.
Repare Therapeutics Inc. (RPTX) Valuation Context
Valued at $114.24M, RPTX is classified as a micro-cap stock. Relative to its peer group, RPTX's quantitative score of 51/100 is below the peer average of 76/100.
Company Profile
Repare Therapeutics Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Montreal, CA. The company is led by CEO Steve Forte. RPTX has traded publicly since 2020.
RPTX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that key stakeholders believe in its potential growth.
- Community sentiment has shifted positively, with discussions highlighting breakthroughs in their cancer therapies, which could drive demand.
- Analysts have noted increasing interest from institutional investors, signaling a potential endorsement of Repare's business model and strategy.
- The company's focus on precision medicine aligns with current healthcare trends, making it a relevant player in an evolving market.
Bear Case
- Some recent clinical trial results have raised questions among investors about the efficacy of their treatments, leading to skepticism in the community.
- Market perception has been affected by broader healthcare sector volatility, causing uncertainty regarding Repare's stability.
- There are concerns about the competitive landscape, as several companies are advancing similar therapies, potentially diluting Repare's market share.
- Negative sentiment has emerged from discussions about funding challenges, which could hinder their ability to execute on strategic initiatives.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
RPTX Latest News
No recent news available for RPTX.
RPTX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for RPTX.
Price Targets
Wall Street price target analysis for RPTX.
RPTX MoonshotScore
What does this score mean?
The MoonshotScore rates RPTX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Steve Forte
CEO
Steve Forte serves as the CEO of Repare Therapeutics Inc. His background includes extensive experience in the biotechnology and pharmaceutical industries. He has held leadership positions at various companies, overseeing drug development, commercialization, and strategic partnerships. Forte's expertise spans across multiple therapeutic areas, with a focus on oncology and precision medicine. He is responsible for managing 129 employees at Repare Therapeutics.
Track Record: Under Steve Forte's leadership, Repare Therapeutics has advanced its pipeline of drug candidates through clinical trials, including RP-3500 and RP-6306. He has also overseen the expansion of the company's SNIPRx platform and the development of new research programs. Key milestones include securing strategic partnerships and raising capital to support the company's growth initiatives.
RPTX Healthcare Stock FAQ
What does Repare Therapeutics Inc. do?
Repare Therapeutics Inc. is a clinical-stage precision oncology company focused on discovering and developing novel cancer therapeutics. The company utilizes its proprietary SNIPRx platform to identify and develop targeted therapies that exploit vulnerabilities in cancer cells, particularly in DNA damage repair pathways. Its lead product candidate, RP-3500, is an oral small molecule inhibitor targeting solid tumors with specific DNA damage repair-related genomic alterations. Repare's business model involves developing and commercializing its own drug candidates, as well as partnering with larger pharmaceutical companies to accelerate the development and commercialization of its pipeline assets.
What do analysts say about RPTX stock?
Analyst coverage of Repare Therapeutics Inc. typically focuses on the company's clinical trial progress, particularly for RP-3500 and RP-6306. Key valuation metrics include the potential market size for its targeted therapies and the likelihood of regulatory approval. Growth considerations include the company's ability to expand the application of its therapies to new cancer types and secure strategic partnerships. Analyst consensus is generally positive, reflecting optimism about the company's technology and pipeline, but also acknowledging the risks associated with clinical-stage biotechnology companies.
What are the main risks for RPTX?
The main risks for Repare Therapeutics Inc. include the inherent uncertainties of clinical drug development, such as unfavorable clinical trial results or regulatory delays. The company also faces competition from other biotechnology and pharmaceutical companies developing similar therapies. Financial risks include a high cash burn rate and the need for additional financing to support ongoing research and development expenses. Additionally, patent expirations and the potential for generic competition pose long-term risks to the company's revenue stream.
How does Repare Therapeutics Inc. navigate regulatory approval processes?
Repare Therapeutics Inc. navigates regulatory approval processes by conducting rigorous clinical trials to demonstrate the safety and efficacy of its drug candidates. The company works closely with regulatory agencies, such as the FDA in the United States and the EMA in Europe, to ensure compliance with all applicable regulations and guidelines. Repare also maintains a strong focus on data integrity and quality control throughout the drug development process. Successful navigation of regulatory approval processes is critical for bringing its therapies to market and generating revenue.
What are the key growth opportunities for RPTX in healthcare?
Repare Therapeutics Inc. has several key growth opportunities in the healthcare sector. These include expanding the application of RP-3500 to new cancer types, advancing RP-6306 and the Polymerase Theta program through clinical trials, securing strategic partnerships with larger pharmaceutical companies, and expanding into new geographic markets. The company's focus on precision oncology and synthetic lethality positions it to capitalize on the growing demand for targeted cancer therapies. Successful execution of these growth strategies could lead to significant revenue growth and increased market share for Repare Therapeutics.
What are the key factors to evaluate for RPTX?
Repare Therapeutics Inc. (RPTX) holds an AI score of 51/100 (moderate). Not financial advice.
How frequently does RPTX data refresh on this page?
RPTX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven RPTX's recent stock price performance?
Repare Therapeutics Inc. (RPTX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary SNIPRx platform for drug discovery. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- Financial data is limited and may not be fully comprehensive.